Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
A group of 20 senators responded to Mylan's recent announcement to expand its drug discount program and release a generic version of the injectable medication, following the controversy over the cost of EpiPens, reports The Wall Street Journal.
Flutiform, an asthma medication developed by Britain-based Vectura Group, proved ineffective at treating chronic obstructive pulmonary disease in a recent late-stage trial, reported Reuters.
U.S Reps. Jason Chaffetz (R-Utah) and Elijah Cummings (D-Md.) of the House Committee on Oversight and Government Reform on Monday sent a letter to Mylan CEO Heather Bresch requesting documents and communications regarding the EpiPen price hike, according to Reuters.
The Food and Drug Administration recently approved a new flu immunization developed by Cambridge, Mass.-based Seqirus.
Drugmakers are pouring money into an increasingly popular marketing tactic — the unbranded ad. In a less regulated attempt to reach consumers, drug companies create ads that seek to educate the public on a specific health condition, one the company…
The Food and Drug Administration granted Fast Track designation for APL-130277, an experimental treatment for Parkinson's disease created by Toronto-based Cynapsus Therapeutics.
The Food and Drug Administration granted emergency use authorization for a new Zika diagnostic test developed by Switzerland-based Roche.
In response to public outrage over the EpiPen price hike, pharmaceutical company Mylan said it will introduce an identical generic version with a wholesale list price of $300 for a pack of two, instead of more than $600 for the…
Former Turing Pharmaceutical CEO Martin Shkreli said via Twitter that insurers should cover some of the cost to make the drug more affordable, according to USA Today.
A bipartisan group of senators on Wednesday sent a letter to Food and Drug Administration Commissioner Robert Califf, MD, urging the agency to help bring more EpiPen competitors to the market.